Rare Endocrine Disorders
Publications
Explore published findings of medical trials and real-world evidence.
This page includes links to Novo Nordisk-sponsored trials and observational research published in peer reviewed journals. The list of publications below is sorted by product and limited to products that have been approved for use. Please note that publications may contain information about doses, delivery devices, uses, formulations and/or populations that differs from FDA-required labeling. Novo Nordisk does not suggest or recommend the use of its products in any manner other than as described in their FDA-required labeling, which is findable under each product below.
Products are listed in order of the most recent FDA approval, with the most recent shown first.
Sogroya®
(somapacitan-beco) injection 5 mg, 10 mg, 15 mg | Full Prescribing Information
Published Date: November 25, 2022
Published Date: April 1, 2020
Published Date: April 1, 2020
Published Date: December 23, 2022
Published Date: September 11, 2023
Norditropin®
(somatropin) injection 5 mg, 10 mg, 15 mg | Full Prescribing Information
No publications available
Published Date: February 24, 2025
Published Date: August 16, 2025
Find more information
Find product information
Explore our portfolio of products for treating rare endocrine disorders, including prescribing information, safety data sheets, and storage and stability information.
Continuing education
Learn about accredited rare endocrine disorders education opportunities supported by Novo Nordisk and provided by third-party organizations.
The purpose of this site is to provide relevant medical and scientific information about Novo Nordisk products and areas of therapeutic interest. Information about investigational products or investigational uses of approved products neither implies FDA approval for these products or uses, nor establishes the safety or efficacy of these products or uses. There is no guarantee that any investigational product or investigational use will receive FDA approval or become commercially available in the United States. Novo Nordisk does not recommend or suggest use of its products in any manner inconsistent with FDA-approved labeling.
This site is intended for United States healthcare professionals only. The information on this site—including all product information—pertains to residents of the United States only. Any products referenced on this site may have different labelling in different countries.
